downgrad neutral pharma thesi intact
kick revisit rate across sector follow
play-out pharma acceler thesi stock current valuat
step sidelin see greater upsid potenti hand
larg cap across space clear thesi hasnt chang
pharma growth acceler driven seri clinic trial read-out label
expans new product approv devic consum still struggl
back acceler pharma busi organ vs
organ js aggreg top line acceler reach
accret actelion acquisit drive minimum ep
growth thru share trade ep
estim line sum-of-the-part estim compani see greater
upsid potenti larg cap name lower rate
neutral overweight
clear remain fundament bullish head
expect pharma-driven acceler continu play lead overal
 growth organ top line devic
consum remain drag strength higher-margin pharma
busi accret actelion acquisit drive ep
growth without much heavi lift top ou cash
repatri enhanc abil pursu increment return
cash sharehold
see busi revenu profit
gener organ growth recent upcom label expans
stelara darzalex imbruvica xarelto recent launch tremfya
off-set new gener biosimilar competit devic
consum busi forecast continu under-perform
consensu outlook pharma busi
consensu devic organ consum
within pharma forecast robust core franchis growth led darzalex
imbruvica stelara xarelto invega sustenna
driver along year one launch tremfya
approv apalutamid off-set competit challeng includ
biosimilar remicad gener zytiga assum oct share loss
continu declin invokana
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
clinic trial catalyst long list posit clinic trial catalyst
start landmark compass trial xarelto zytiga latitud trial
newli diagnos metastat prostat cancer patient initi first-lin data darzalex
alcyon trial key trial look includ result
phase spartan aci trial apalutamid castration-resist prostat cancer
nda submit decemb fda approv late first seri
phase trial intranas esketamin treatment-resist depress transform-
phase data xarelto ischem hf
patient command hf post-hospit discharg patient marin
multitud phase ii trial test imbruvica combin treatment
believ pharma remain posit outperform less confid
balanc busi forecast medic devic growth organ
 manag exit anima insulin deliveri busi consum
model flattish sale organ follow difficult challeng
environ across sector told lead us model organ growth
ep growth assum new asset sale headwind current fx
rate tailwind limit capit deploy made sever minor
adjust model result slight chang ep estim
current level trade project ep line sum-of-the-
part estim devic consum busi reacceler one could argu
multipl expans absenc higher top-lin growth greater contribut
current under-perform busi expect rel multipl expans
limit year-end price target line js sotp estim
impli upsid current level
invest thesi valuat risk
kick revisit rate across sector follow play
pharma acceler thesi stock perform step
sidelin see greater upsid potenti hand larg cap
across space clear thesi hasnt chang pharma growth
acceler driven seri clinic trial read-out label expans new
product approv devic consum still struggl back
acceler pharma busi organ vs organ js
aggreg top-lin acceler reach accret
actelion acquisit drive minimum ep growth thru
share trade ep estim line
sum part see greater upsid potenti larg cap name
lower rate neutral overweight
current level trade project ep line sum-of-its-
part devic consum busi reacceler one could argu
multipl expans absenc higher top-lin greater contribut
current under-perform busi expect rel multipl expans
limit year-end price target line js sotp number
impli upsid current level
 sotp valu pharma busi ep peer
medic devic busi peer
consum busi peer cl
risk rate price
upsid risk neutral rate price target includ re-acceler
medic devic consum busi dramat acceler xarelto growth
post-label expans effect alloc capit buyback valu
downsid risk neutral rate price target includ increas price
pressur us pharmaceut busi neg outcom key clinic trial
current pipelin pharma product competit product launch chang
us healthcar system compani product liabil exposur
johnson johnson summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
